The BioTech hiring market took a hard hit in 2023 and through much of 2024. Rising interest rates, a difficult IPO window, and a significant pullback in venture funding produced a wave of layoffs, freezes, and restructures across the sector. For talent teams, it was a long stretch of doing more with less.
That period isn’t entirely behind us, but the direction has shifted. Funding is returning to specific sub-sectors. Mandates that were paused are reopening. And the talent market, which briefly moved in employers’ favor, is tightening again as demand recovers faster than supply.
This piece is for Heads of Talent, VPs of People, and founders who want to understand where the recovery is happening, which roles are moving first, and what to do now before the window closes.
Where the Recovery Is Coming From
The BioTech recovery isn’t uniform. It’s concentrated in sub-sectors where the investment thesis stayed strong (or got stronger) through the downturn.
AI-driven drug discovery has kept attracting capital throughout the contraction. Advances in computational biology, large language model applications in molecular design, and the efficiency case for AI in early-stage development have kept this corner of the market largely insulated from the broader funding squeeze. Companies here have been hiring through the freeze, and competition for ML scientists, computational chemists, and bioinformaticians has intensified as a result.
Metabolic health and GLP-1 adjacent platforms have been the standout growth story of the past 18 months. The commercial success of weight loss and metabolic therapeutics has driven serious investment into digital companion platforms, monitoring technology, and next-generation metabolic health products. The talent implications are still accelerating.
Genomics and precision medicine have also held up well – supported by progress in polygenic risk scoring, the growth of population health genomics programs, and increasing clinical adoption of genomic diagnostics. Companies in this space have been selective, but they haven’t stopped hiring.
The slowest recovery is in sub-sectors most dependent on late-stage clinical trial funding and public market sentiment: traditional drug development without a clear AI or platform angle, and medical device companies outside the digital health space. Mandates are reopening there, but more cautiously and with tighter headcount constraints.
The Roles Coming Back First
Not every function is recovering at the same speed. Knowing which roles are moving first helps talent teams focus their energy – and avoid the mistake of waiting until the market has fully recovered before acting.
Computational and Data Science Roles
ML scientists, bioinformaticians, computational biologists, and health data scientists are in demand across almost every BioTech sub-sector that’s actively hiring right now. These were among the first roles paused during the freeze and are among the first to reopen, reflecting how central data and AI capability has become to the current investment thesis across the board.
Regulatory Affairs and Clinical Development
As companies restart paused clinical programs, regulatory affairs and clinical development hires are coming back with real urgency. The profiles most in demand are regulatory strategists with IND and NDA experience in the US, and regulatory affairs leads with EMA and MHRA experience in Europe. Clinical program managers with experience restarting paused trials are also in short supply and moving quickly.
Commercial and Market Access
BioTech companies approaching commercialization are rebuilding their commercial functions faster than those still in development. Market access specialists, health economics leads, and VP-level commercial hires are all active right now – particularly at companies preparing for launch or re-launch after a period of retrenchment.
Senior Leadership and Executive Hires
Board-level and C-suite mandates are reopening as companies reconfigure their leadership for the recovery phase. Chief Scientific Officers, Chief Medical Officers, and VP-level R&D leaders are among the most active searches in the market. These are exactly the mandates where a proactive executive search approach – rather than advertising – is most likely to find the right candidate quickly. The people best suited to these roles aren’t browsing job boards.
What Talent Teams Should Do Now
The window between a market beginning to recover and that recovery becoming fully visible in the talent pool is usually short. Companies that move during this window consistently outperform those that wait for certainty before acting.
Rebuild Your Talent Pipeline Before You Need It
The freeze created a large pool of available BioTech talent that’s now being absorbed quickly. Candidates who were available six months ago on flexible terms are increasingly in roles or in active conversations. Rebuilding your pipeline now (even for roles that aren’t immediately open) puts you in a much stronger position when mandates do land. Talk to your HealthTech recruitment partner now rather than when the pressure is on.
Don’t Wait for Final Budget Approval to Start the Search
In a recovering market, the time between budget approval and a strong shortlist is longer than it was during the freeze. Starting the scoping and briefing process before final approval arrives means you can move to offer stage quickly when the mandate is formally open, rather than starting from scratch at that point.
Revisit Compensation Benchmarks
The freeze saw some compression in candidate expectations as people prioritized security over premium packages. That compression is unwinding. Talent teams still benchmarking against 2023 or 2024 data are likely to find their offers are no longer competitive. Refreshing benchmarks now avoids the frustrating (and expensive) outcome of losing a candidate at offer stage after a strong process.
Prioritize Speed in the Process
The candidates most in demand right now are moving fast. A process that runs to six interview stages over eight weeks will consistently lose the best people to organizations that can move to offer in two to three weeks. For senior and specialist hires, streamlining the process is one of the highest-impact things a talent team can do right now.
How Storm3 Supports BioTech Hiring in the Recovery
Storm3’s BioTech recruitment team has stayed active throughout the freeze and is well placed to support companies that need to move quickly now. Our network spans AI Drug Discovery, Real World Evidence, Genomics & Genetics, and the broader HealthTech landscape. We know which sub-sectors are moving fastest and where the real talent competition is concentrated.
Ready to get ahead of the recovery? Submit your vacancy and our team will be in touch.
